Upadacitinib for Spondyloarthritis; A new treatment option.

Ann Med Surg (Lond) · 2022 · PMC9577587 · PMID 36268430

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

According to research by Deodhar, Atul et al., patients who were using Upadacitinib 15 mg had a highly significant ( p < 0.0001) ASAS40 (Assessment of SpondyloArthritis International Society 40%) response (45%) at week 14 compared to those receiving a placebo (23%) [ 3 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.